文献速递肾癌与肾肿瘤

小肾肿块患者主动监测与手术或消融治疗的肿瘤学结局:系统综述与定量分析

Oncological Outcomes of Active Surveillance versus Surgery or Ablation for Patients with Small Renal Masses: A Systematic Review and Quantitative Analysis.
PubMed 文献 · Eur Urol Oncol · 2024-10-24

该系统综述纳入8项比较研究共4947例小肾肿块患者,评估主动监测与手术或消融的肿瘤学结局。合并SEER数据时手术组总生存率显著更高(HR 0.73,p=0.007),尤其部分肾切除术(HR 0.62,p<0.001);排除SEER后总体OS无显著差异(HR 0.84,p=0.3),但部分肾切除亚组OS仍长于主动监测组(HR 0.6,p=0.002)。仅SEER研究显示癌症特异性生存有显著差异。

要点

  • 合并SEER数据时手术组总生存率显著高于主动监测组(HR 0.73,p=0.007)。
  • 排除SEER后主动监测与手术总体OS无显著差异(HR 0.84,p=0.3)。
  • 部分肾切除亚组OS长于主动监测组(HR 0.6,p=0.002)。

核心结论

  • 接受主动监测的患者总生存率与手术或消融治疗者相似,但解读数据需谨慎,因存在选择偏倚和主动监测方案差异。
  • 本综述强调需要个体化共享决策,以识别最可能从主动监测获益的小肾肿块患者。

研究设计与样本

  • 2024年4月检索PubMed、Scopus和Web of Science,纳入比较主动监测与小肾肿块手术干预的研究(PROSPERO:CRD42024530299)。
  • 共纳入8项符合条件的研究(3项前瞻性、4项回顾性、1项基于监测、流行病学和最终结果[SEER]数据),涉及4947例患者。
  • 采用随机效应模型进行定量分析,主要结局为总生存率和癌症特异性生存率。

主要发现

  • 合并SEER数据集的数据显示,接受手术干预的患者总生存率显著更高(HR 0.73;p=0.007),尤其是部分肾切除术(HR 0.62;p<0.001)。
  • 排除SEER数据集的敏感性分析中,主动监测与手术干预总体上总生存率无显著差异(HR 0.84;p=0.3),但部分肾切除亚组总生存期长于主动监测组(HR 0.6;p=0.002)。
  • 仅基于SEER数据集的研究显示癌症特异性生存率有显著差异。

关键数值与推荐

  • 合并SEER数据:手术干预组 vs 主动监测组总生存率HR 0.73(p=0.007),部分肾切除组 vs 主动监测组HR 0.62(p<0.001)。
  • 排除SEER数据:手术干预组 vs 主动监测组总生存率HR 0.84(p=0.3),部分肾切除组 vs 主动监测组HR 0.6(p=0.002)。

临床怎么用

  • 原文结论未据此给出具体推荐。

局限性

  • 回顾性研究存在选择偏倚。
  • SEER数据库研究中的干预分类存在问题。
  • 主动监测方案存在差异,解读数据需谨慎。
  • 证据仍然有限,需要更多研究来帮助识别主动监测的最佳候选者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: While active surveillance (AS) is an alternative to surgical interventions in patients with small renal masses (SRMs), evidence regarding its oncological efficacy is still debated. We aimed to evaluate oncological outcomes for patients with SRMs who underwent AS in comparison to surgical interventions. METHODS: In April 2024, PubMed, Scopus, and Web of Science were queried for comparative studies evaluating AS in patients with SRMs (PROSPERO: CRD42024530299). The primary outcomes were overall (OS) and cancer-specific survival (CSS). A random-effects model was used for quantitative analysis. KEY FINDINGS AND LIMITATIONS: We identified eight eligible studies (three prospective, four retrospective, and one study based on Surveillance, Epidemiology and End Results [SEER] data) involving 4947 patients. Pooling of data with the SEER data set revealed significantly higher OS rates for patients receiving surgical interventions (hazard ratio [HR] 0.73; p = 0.007), especially partial nephrectomy (PN; HR 0.62; p < 0.001). However, in a sensitivity analysis excluding the SEER data set there was no significant difference in OS between AS and surgical interventions overall (HR 0.84; p = 0.3), but the PN subgroup had longer OS than the AS group (HR 0.6; p = 0.002). Only the study based on the SEER data set showed a significant difference in CSS. The main limitations include selection bias in retrospective studies, and classification of interventions in the SEER database study. CONCLUSIONS AND CLINICAL IMPLICATIONS: Patients treated with AS had similar OS to those who underwent surgery or ablation, although caution is needed in interpreting the data owing to the potential for selection bias and variability in AS protocols. Our review reinforces the need for personalized shared decision-making to identify patients with SRMs who are most likely to benefit from AS. PATIENT SUMMARY: For well-selected patients with a small kidney mass suspicious for cancer, active surveillance seems to be a safe alternative to surgery, with similar overall survival. However, the evidence is still limited and more studies are needed to help in identifying the best candidates for active surveillance.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Tsuboi I, Rajwa P, Campi R, et al. Oncological Outcomes of Active Surveillance versus Surgery or Ablation for Patients with Small Renal Masses: A Systematic Review and Quantitative Analysis. Eur Urol Oncol. 2024. PMID: 39455341. doi:10.1016/j.euo.2024.10.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。